Mitsiades N - Search Results

1

Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.

Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Mitsiades N. Mitsiades CS, et al. Among authors: mitsiades n. J Clin Endocrinol Metab. 2006 Sep;91(9):3662-6. doi: 10.1210/jc.2006-0055. Epub 2006 Jul 5. J Clin Endocrinol Metab. 2006. PMID: 16822827

2

Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma.

Huang Q, Mitsiades I, Dowst H, Zarrin-Khameh N, Noor AB, Castro P, Scheurer ME, Godoy G, Mims MP, Mitsiades N. Huang Q, et al. Among authors: mitsiades n, mitsiades i. NPJ Precis Oncol. 2023 Nov 18;7(1):123. doi: 10.1038/s41698-023-00467-9. NPJ Precis Oncol. 2023. PMID: 37980380 Free PMC article.

3

Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis.

Mitsiades N, Poulaki V, Kotoula V, Mastorakos G, Tseleni-Balafouta S, Koutras DA, Tsokos M. Mitsiades N, et al. J Clin Endocrinol Metab. 1998 Jun;83(6):2199-203. doi: 10.1210/jcem.83.6.4853. J Clin Endocrinol Metab. 1998. PMID: 9626160

4

Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase.

Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M. Mitsiades N, et al. Am J Pathol. 1998 Dec;153(6):1947-56. doi: 10.1016/S0002-9440(10)65708-2. Am J Pathol. 1998. PMID: 9846984 Free PMC article.

5

Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.

Mitsiades N, Poulaki V, Mastorakos G, Tseleni-Balafouta ST, Kotoula V, Koutras DA, Tsokos M. Mitsiades N, et al. J Clin Endocrinol Metab. 1999 Aug;84(8):2924-32. doi: 10.1210/jcem.84.8.5917. J Clin Endocrinol Metab. 1999. PMID: 10443700

6

Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors.

Mitsiades N, Poulaki V, Leone A, Tsokos M. Mitsiades N, et al. J Natl Cancer Inst. 1999 Oct 6;91(19):1678-84. doi: 10.1093/jnci/91.19.1678. J Natl Cancer Inst. 1999. PMID: 10511596

7

Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.

Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Mitsiades N, et al. Cancer Res. 2000 Aug 1;60(15):4122-9. Cancer Res. 2000. PMID: 10945619

8

Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves' disease.

Mitsiades N, Poulaki V, Tseleni-Balafouta S, Chrousos GP, Koutras DA. Mitsiades N, et al. Thyroid. 2000 Jul;10(7):527-32. doi: 10.1089/thy.2000.10.527. Thyroid. 2000. PMID: 10958304

9

Circulating thyroglobulin transcytosed by thyroid cells in complexed with secretory components of its endocytic receptor megalin.

Marinò M, Chiovato L, Mitsiades N, Latrofa F, Andrews D, Tseleni-Balafouta S, Collins AB, Pinchera A, McCluskey RT. Marinò M, et al. Among authors: mitsiades n. J Clin Endocrinol Metab. 2000 Sep;85(9):3458-67. doi: 10.1210/jcem.85.9.6804. J Clin Endocrinol Metab. 2000. PMID: 10999849 Clinical Trial.

10

Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.

Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Mitsiades N, et al. Cancer Res. 2001 Jan 15;61(2):577-81. Cancer Res. 2001. PMID: 11212252

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

170 results

Search Page

Filters